APPENDIX A

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.221; Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura and No.293; Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Company/sponsor • Amgen UK (romiplostim) • Novartis Pharmaceuticals (eltrombopag) Patient/carer groups • Black Health Agency • Equalities National Council • ITP Support Association • Muslim Council of Britain • South Asian Health Foundation • Specialised Healthcare Alliance • Splenectomy Trust UK Professional groups • Association of Anaesthetists • Association of Surgeons of Great Britain and Ireland • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Society for Haematology • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • UK ITP Forum • United Kingdom Clinical Pharmacy Association	General commentators • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Comparators • Accord UK (azathioprine, mycophenolate mofetil, dapsone) • Aspen (azathioprine) • Baxter Healthcare (cyclophosphamide) • Dexcel Pharma (ciclosporin) • Hospira UK (vinblastine, vincristine) • Mylan UK (azathioprine, mycophenolate mofetil, ciclosporin, danazol) • Napp Pharmaceuticals (rituximab) • Novartis (ciclosporin)

Others • Department of Health and Social Care • NHS Bristol CCG • NHS England • NHS Gloucestershire CCG • Welsh Government	• Roche Products (mycophenolate mofetil, rituximab) • Sandoz (rituximab, azathioprine, cyclophosphamide) • Sanofi (danazol) • Santen UK (ciclosporin) • Teva Pharma (mycophenolate mofetil) Relevant research groups • MRC Clinical Trials Unit • National Institute for Health Research Associated Public Health Groups • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary.

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.

